Aligos Therapeutics (ALGS) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aligos Therapeutics (ALGS) has outperformed Quince Therapeutics (QNCX) over the past year, losing 45.9% versus a loss of 92.5%. Over five years, ALGS leads with a -98.7% price change compared with -99.8% for QNCX. Aligos Therapeutics is the larger company by market cap ($33.2 million vs $29.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | QNCX |
|---|---|---|
| Share price | $5.31 | $29.36 |
| Market cap | $33.16M | $29.86M |
| 1-day change | -0.19% | +9.88% |
| YTD return | -42.92% | -96.01% |
| 1-year return | -45.93% | -92.49% |
| 5-year return | -98.66% | -99.79% |
| EPS (TTM) | $-7.41 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $910.00 |
| 52-week low | $3.98 | $15.10 |
| Distance from 52-week high | -61.21% | -96.77% |
| Average volume | 91.45K | 28.49K |
| Shares outstanding | 5.44M | 1.02M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALGS has outperformed QNCX by 46.6 percentage points over the past year.
ALGS vs QNCX FAQ
Which is bigger, Aligos Therapeutics or Quince Therapeutics?
Aligos Therapeutics (ALGS) is larger, with a market capitalization of $33.16M compared with $29.86M for Quince Therapeutics (QNCX).
Which stock has performed better over the past year, ALGS or QNCX?
ALGS returned -45.93% over the past 12 months, compared with -92.49% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.